week 1 tirzepatide results TrimRX Apitegromab for lean mass preservation

Gorgojo-Martinez J, et al

This sample size provides at least 80% power for the comparison of tirzepatide versus placebo for the change in energy intake during ad libitum test meals (primary outcome) based on a two-sample t -test at an alpha level of 0.05, given an expected treatment difference of 212 kcal and an assumed common standard deviation of 289 kcal for the change in energy intake from baseline

Independent third-party testing verifies purity, identity, and batch specifications prior to release

For doses of 2mg to 4mg, 5mg/mL (2mL per 10mg vial) gives manageable draw volumes

If you then maintain at 12mg weekly for 24 additional weeks (6 months), you need roughly 288mg more, or about 14-15 additional vials

This assumption can be misleading and dangerous